ADC Therapeutics SA – NYSE:ADCT
ADC Therapeutics SA stock price today
$3.23
+1.20
+59.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
ADC Therapeutics SA stock price monthly change
-46.86%
month
ADC Therapeutics SA stock price quarterly change
-46.86%
quarter
ADC Therapeutics SA stock price yearly change
+18.02%
year
ADC Therapeutics SA key metrics
Market Cap | 189.51M |
Enterprise value | N/A |
P/E | -1.04 |
EV/Sales | -0.24 |
EV/EBITDA | 0.28 |
Price/Sales | 0.91 |
Price/Book | 1.86 |
PEG ratio | -0.03 |
EPS | -2.75 |
Revenue | 68.61M |
EBITDA | -129.45M |
Income | -226.56M |
Revenue Q/Q | -4.94% |
Revenue Y/Y | -62.38% |
Profit margin | -96.18% |
Oper. margin | -80.95% |
Gross margin | 97.33% |
EBIT margin | -80.95% |
EBITDA margin | -188.66% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeADC Therapeutics SA stock price history
ADC Therapeutics SA stock forecast
ADC Therapeutics SA financial statements
| Jun 2023 | 19.28M | -47.11M | -244.34% |
|---|---|---|---|
| Sep 2023 | 14.49M | -47.80M | -329.86% |
| Dec 2023 | 16.79M | -85.03M | -506.44% |
| Mar 2024 | 18.05M | -46.60M | -258.16% |
| Mar 2024 | 18.05M | -46.60M | -258.16% |
|---|---|---|---|
| Sep 2025 | 12.19M | -36.72M | -301.24% |
| Oct 2025 | 23.44M | -36.04M | -153.79% |
| Dec 2025 | 24.52M | -36.59M | -149.23% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 507302000 | 515.89M | 101.69% |
|---|---|---|---|
| Sep 2023 | 466900000 | 521.08M | 111.6% |
| Dec 2023 | 354782000 | 503.03M | 141.79% |
| Mar 2024 | 307966000 | 502.41M | 163.14% |
| Jun 2023 | -36.82M | -1.01M | 74.73M |
|---|---|---|---|
| Sep 2023 | -34.01M | -661K | -2.30M |
| Dec 2023 | -33.07M | -527K | 1.63M |
| Mar 2024 | -44.09M | -531K | 356K |
ADC Therapeutics SA alternative data
| Aug 2023 | 317 |
|---|---|
| Sep 2023 | 317 |
| Oct 2023 | 317 |
| Nov 2023 | 317 |
| Dec 2023 | 317 |
| Jan 2024 | 317 |
| Feb 2024 | 317 |
| Mar 2024 | 273 |
| Apr 2024 | 273 |
| May 2024 | 273 |
| Jun 2024 | 273 |
| Jul 2024 | 273 |
ADC Therapeutics SA other data
23.23%
-26.32%
of ADCT is owned by hedge funds
29
-31
18.15M
-20.67M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 1332876 | 0 |
| Feb 2024 | 484616 | 0 |
| May 2024 | 14270446 | 29731 |
| Jun 2024 | 0 | 32047 |
| Jul 2024 | 800000 | 0 |
| Dec 2024 | 200000 | 25352 |
| Patent |
|---|
Application Filling date: 18 Mar 2022 Issue date: 8 Sep 2022 |
Grant Filling date: 8 Feb 2018 Issue date: 12 Jul 2022 |
Application Filling date: 8 Feb 2019 Issue date: 9 Jun 2022 |
Grant Filling date: 14 Jun 2018 Issue date: 3 May 2022 |
Application Filling date: 22 May 2019 Issue date: 14 Apr 2022 |
Application Filling date: 22 Sep 2021 Issue date: 31 Mar 2022 |
Application Filling date: 30 Jul 2021 Issue date: 3 Feb 2022 |
Application Filling date: 20 Jul 2021 Issue date: 20 Jan 2022 |
Application Filling date: 20 Apr 2018 Issue date: 20 Jan 2022 |
Application Filling date: 24 Sep 2021 Issue date: 13 Jan 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 13 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
ADC Therapeutics: Navigating A Swirling Drain
ADC Therapeutics: Slowly Moving Toward Solvency
AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet)
ADC Therapeutics: Running Through A Stretch Of Bad Luck
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of ADC Therapeutics SA stock today?
One share of ADC Therapeutics SA stock can currently be purchased for approximately $3.23.
-
When is ADC Therapeutics SA's next earnings date?
Unfortunately, ADC Therapeutics SA's (ADCT) next earnings date is currently unknown.
-
Does ADC Therapeutics SA pay dividends?
No, ADC Therapeutics SA does not pay dividends.
-
How much money does ADC Therapeutics SA make?
ADC Therapeutics SA has a market capitalization of 189.51M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 66.86% to 69.56M US dollars.
-
What is ADC Therapeutics SA's stock symbol?
ADC Therapeutics SA is traded on the NYSE under the ticker symbol "ADCT".
-
What is ADC Therapeutics SA's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ADC Therapeutics SA?
Shares of ADC Therapeutics SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does ADC Therapeutics SA have?
As Jul 2024, ADC Therapeutics SA employs 273 workers.
-
When ADC Therapeutics SA went public?
ADC Therapeutics SA is publicly traded company for more then 5 years since IPO on 18 May 2020.
-
What is ADC Therapeutics SA's official website?
The official website for ADC Therapeutics SA is adctherapeutics.com.
-
How can i contact ADC Therapeutics SA?
ADC Therapeutics SA can be reached via phone at +41 21 653 02 00.
ADC Therapeutics SA company profile:
ADC Therapeutics SA
adctherapeutics.comExchange:
NYSE
Full time employees:
273
Industry:
Biotechnology
Sector:
Healthcare
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Biopole
Epalinges, 1066
Epalinges, 1066
CIK: 0001771910
ISIN: CH0499880968
CUSIP: H0036K147
